Purpose: Because of our incomplete understanding of the pathogenesis of Peyronie's disease (PD), management of PD remains a therapeutic dilemma in the field of sexual medicine. Most currently available medical treatments have not demonstrated conclusive effects. The present review addresses the current status of nonsurgical treatment and emerging new therapeutic targets for PD. Materials and Methods: A systematic review of clinical or preclinical results of nonsurgical treatment for PD published as original articles in peer-reviewed journals is provided. Results: Although many studies regarding nonsurgical treatment of PD showed positive outcomes, the majority of these studies were not placebo-controlled approaches. Currently available randomized controlled trials on the use of oral, intralesional injection, and topical agents have not showed conclusive effects, with minor or little effect. However, the outcomes of recent preclinical studies targeting the TGF-β pathway or NO-cGMP pathway are promising. Conclusions: There is no viable therapeutic option for PD between watchful waiting and surgical manipulation. With further research into the pathologic cascade of cellular and molecular events and an increase in our understanding of the pathophysiology of PD using animal models, the development of novel and effective medical therapies will become a realistic objective. (Korean J Urol 2009;50:527-533)
INTRODUCTION
Peyronie's disease (PD), which affects 3.2-8.9% of the male population, is characterized by localized fibrotic plaques in the tunica albuginea. 1, 2 These plaques impede the expansion of the tunica albuginea during erection, which results in penile bending and often pain. The etiology of PD is not fully delineated, but an inflammatory process and subsequent aberrant wound healing triggered by repetitive trauma to the penis during intercourse has gained widespread acceptance. 3, 4 However, management of PD remains a therapeutic dilemma in the field of sexual medicine. Due to our incomplete understanding of the pathogenesis of PD, the nonsurgical or medical treatment of this entity has progressed little and has not kept pace with the surgical treatment of this condition. This discrepancy has led to tremendous frustration among patients who do not wish to proceed with surgical correction but for whom the pain, disfigurement, and sexual dysfunction are a constant source of anxiety and distress. The present review addresses the current status of nonsurgical treatment and recent investigations into basic science and therapeutic advances in the management of PD.
CURRENT MEDICAL TREATMENT
Multiple nonsurgical remedies including a variety of oral, injectable, and topical agents, as well as noninvasive techniques : propionyl-L-carnitine and vitamin E were given separately or in combination 
Intralesional injection therapy
In a recent review by Russel et al, 5 90% of the studies regarding intralesional injection therapy for PD showed positive outcomes. Unfortunately, most of those studies did not offer convincing evidence-based data, with only 4 placebo-controlled trials being available ( Table 2) . [15] [16] [17] [18] However, the power of the former 2 studies was hampered by their small patient populations (27 in the control and 22 in the treatment arm for the collagenase study; 7 in the control and 7 in the treatment arm for the verapamil study). The results of this study were encouraging in that subjects receiving interferon injections experienced improvement in penile curvature, decreased plaque size and density, and reduced pain compared with those who received intralesional and freedom from pain during erection, showed significant improvements from baseline. 21 However, a double-blind, placebo-controlled multicenter study is required for further validation.
Topical or transdermal therapy
A previous study reported that the transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. 22 To enhance transdermal drug transport, new techniques have been introduced, such as iontophoresis or electromotive drug administration (EMDA) using electrokinetic transport of charged (ionic) molecules for enhancement of transdermal drug transport into diseased tissue. 23 In a randomized controlled study with 5 mg verapamil and 8 mg dexamethasone, a response was observed by a reduction of plaque size in 100%, a response on curvature in 57%, and a response on pain in 76%, which were statistically significant compared with the control group. 24 However, a recent double-blind, placebo-controlled trial to determine the effectiveness of verapamil delivered through EMDA failed to show improvement in penile curvature. 25 Further study is needed to determine whether EMDA may play a role in the treatment of PD and whether verapamil or other agents delivered via EMDA may exert a therapeutic effect.
A randomized, placebo-controlled series using liposomal recombinant human superoxide dismutase revealed a significant decrease in penile pain compared with the placebo group. 26 However, no significant difference in penile curvature or plaque size was noted between groups. 26 The result of placebocontrolled trials on the use of topical or transdermal therapy is summarized in Table 3 .
Extracorporeal shock wave therapy
The data published so far do not justify considering extracorporeal shock wave therapy as an evidence-based standard procedure for the treatment of PD. It may be beneficial only to achieve freedom from pain within a short time.
6,27
Most of the currently available nonsurgical treatment moda- 
FUTURE PERSPECTIVES
Currently, surgical intervention is the only efficacious treatment for PD. Despite the relatively high prevalence of PD, very little scientific information is known about this condition, which is reflected by the lack of any medical treatment to definitively alter the progression of the disorder. Therefore, novel forms of treatment for PD are needed and may emerge (Table 4 ).
Inhibition of transforming growth factor-β signaling
Transforming growth factor-β1 (TGF-β1) has been identified as the most relevant fibrogenic cytokine and is known to be upregulated in both human PD plaque 28 and in the PD-like plaque of the rat model. 29 ALK5 inhibition has been reported to attenuate the tissue fibrosis in kidney, lung, and liver.
42-44
Recently, we further elucidated the molecular mechanism of PD and have uncovered potential targets for molecular-based therapies. 45 In that study, we determined the effectiveness of 
Activation of nitric oxide-cGMP pathway
It is thought that nitric oxide (NO) produced by inducible nitric oxide synthase (iNOS) has anti-fibrotic actions in the rat, A recent study reported that myostatin was overexpressed in human PD plaque. 56 Furthermore, myostatin elicited a PD-like plaque in the rat and intensified the plaque triggered by TGF-β 1. The authors suggested that anti-fibrotic therapies aimed at inhibiting both the myostatin and the TGF-β pathways would be more effective than blocking the pathways individually.
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CONCLUSION
Although none of the currently available nonsurgical treatment modalities is efficacious for preventing the progression of PD, the results of recent preclinical studies targeting the TGF-β pathway or NO-cGMP pathway are promising. With further research into the pathologic cascade of cellular and molecular events and an increase in our understanding of the pathophysiology of PD using animal models, the development of novel and effective medical therapies will become a realistic objective.
